Mycobacterium chelonae keratitis:Resolution after debridement and presoaked collagen shields

We report a case of Mycobacterium chelonae keratitis following corneal injury by a foreign body. Diagnosis was made by Ziehl-Neelsen staining and Lowenstein-Jensen culture of corneal scrapings. On the basis of the in vitro susceptibility testing, the patient was treated with topical fortified amikacin. Given the lack of response to this therapy, we decided to carry out a debridement of the infiltrative areas to eliminate infected tissue, and to use an amikacin-soaked collagen shield supplemented every 4 h with topical fortified amikacin to promote healing of the debrided area and to potentiate the effects of the antibiotic therapy. After this treatment, clinical resolution was observed and a further acid-fast stain and culture for mycobacterium were negative. Debridement of the infiltrative areas could be used in cases of mycobacterium keratitis when early diagnosis is made and before the corneal infection has become widespread.

Anchored in Irish housing tradition, Bog West: Steve Larkin's rural house resonates with its surroundings and tectonically celebrates domestic life

Full length critical peer review article about House at Bogwest by architect Emmett Scanlon writing for A10. Included visit to the house and an interview with Steve Larkin. Photographs by Alice Clancy. Photographs and plans describing House at Bogwest.

House at Bogwest in County Wexford, Ireland by Steve Larkin Architects

Publication associated with AR House awards 2012 by the Architectural Review. Text includes citation by Jury and based on interview / text with Steve Larkin. Drawings by Steve Larkin and photographs by Alice Clancy.

House in Bogwest, Steve Larkin Architects:Award

2012 AAI Awards Publication by Gandon Editions. Award winning House in Bogwest by Steve Larkin Architects. Includes text by Steve Larkin Architects, Peer Review text by AAI awards 2012 international jury of Architects including Joseph Rykwert, Keith Williams, Noel Brady, Michael McGarry and Ruairí Ó Cuív, Drawings by Steve Larkin and Photographs by Alice Clancy.

House at Bogwest, Wexford, Ireland: Steve Larkin Architect

Critical review of House at Bogwest by Steve Larkin Architects. Text by editorial team, drawings by Steve Larkin and photographs by Alice Clancy.

Primary airway epithelial cell culture and asthma in children-lessons learnt and yet to come

Until recently the airway epithelial cell (AEC) was considered a simple barrier that prevented entry of inhaled matter into the lung parenchyma. The AEC is now recognized as having an important role in the inflammatory response of the respiratory system to inhaled exposures, and abnormalities of these responses are thought to be important to asthma pathogenesis. This review first explores how the challenges of studying nasal and bronchial AECs in children have been addressed and then summarizes the results of studies of primary AEC function in children with and without asthma. There is good evidence that nasal AECs may be a suitable surrogate for the study of certain aspects of bronchial AEC function, although bronchial AECs remain the gold standard for asthma research. There are consistent differences between children with and without asthma for nasal and bronchial AEC mediator release following exposure to a range of pro-inflammatory stimulants including interleukins (IL)-1β, IL-4, and IL-13. However, there are inconsistencies between studies, e.g., release of IL-6, an important pro-inflammatory cytokine, is not increased in children with asthma relative to controls in all studies. Future work should expand current understanding of the "upstream" signalling pathways in AEC, study AEC from children before the onset of asthma symptoms and in vitro models should be developed that replicate the in vivo status more completely, e.g., co-culture with dendritic cells. AECs are difficult to obtain from children and collaboration between centers is expected to yield meaningful advances in asthma understanding and ultimately help deliver novel therapies.